GTF2H4 and head and neck squamous cell carcinoma: Out of the60 genes, 12 genes have crystal structures and druggable potential.We show that genes such as GTF2H4, HAUS7, MSN, and MNDA could be targetsof Pembrolizumab and Nivolumab, which are approved monoclonal antibodiesfor HNSCC.